 Home > Biochemistry News > Biotechnology News > Reduce the risk of breast cancer recurrence by 42%. Olapali Phase 3 clinical results are positive

Reduce the risk of breast cancer recurrence by 42%. Olapali Phase 3 clinical results are positive

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

cancer injection treatment

stage 3 myeloma

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, AstraZeneca and Merck (MSD) jointly announced that the PARP inhibitor Olapali (English trade name Lynparza), jointly developed by the two parties, is used in the treatment of high-risk HER2-negative early stage with germline BRCA mutation (gBRCAm) Positive results were obtained in phase 3 clinical trials of breast cancer

The Phase 3 clinical trial called OlympiA is a double-blind, placebo-controlled multicenter clinical trial

The results of the test showed that after 3 years of treatment, 85.

▲Efficacy results of olaparib in the Phase 3 clinical trial of OlympiA (picture source: reference [1])

In 2020, approximately 2.

Note: The original text has been deleted

Reference materials:

[1] Lynparza reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.